Skip to main content
OpenTrials

Clinical trial condition

Immunologic Deficiency Syndromes

Explore clinical trials studying Immunologic Deficiency Syndromes. Study availability and eligibility vary by location and protocol.

6,128 public trials 394 recruiting studies
Refine in advanced search Browse all conditions

Immunologic Deficiency Syndromes trial results

Completed

Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants

NCT00350272

Conditions
Blood-Borne Infections, Communicable Diseases, Genital Diseases, +11 more
Locations
  • Clinical Trial Site Little Rock, Arkansas, United States
  • Clinical Trial Site Long Beach, California, United States
  • Clinical Trial Site Los Angeles, California, United States
  • Clinical Trial Site Washington D.C., District of Columbia, United States
View all 26 locations
View Trial Details
Completed

Study of Once Daily Elvucitabine Versus Lamivudine in Participants With a Documented M184V Mutation

NCT00312039

Conditions
Blood-Borne Infections, Communicable Diseases, Genital Diseases, +11 more
Locations
  • Clinical Trial Site Birmingham, Alabama, United States
  • Clinical Trial Site Sacramento, California, United States
  • Clinical Trial Site Miami, Florida, United States
  • Clinical Trial Site Orlando, Florida, United States
View Trial Details
Completed

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)

NCT02831673

Conditions
Acquired Immunodeficiency Syndrome, Blood-Borne Infections, Communicable Diseases, +14 more
Locations
  • GSK Investigational Site Phoenix, Arizona, United States
  • GSK Investigational Site Washington D.C., District of Columbia, United States
  • GSK Investigational Site Ft. Pierce, Florida, United States
  • GSK Investigational Site Orlando, Florida, United States
View all 90 locations
View Trial Details
Completed

Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients

NCT02741323

Conditions
Blood-Borne Infections, Communicable Diseases, Female Urogenital Diseases, +16 more
Locations
  • UAB HIVTR-CCR5 Non-Network CRS Birmingham, Alabama, United States
  • UCLA HIVTR-CCR5 Non-Network CRS Los Angeles, California, United States
  • UCSF HIVTR-CCR5 Non-network CRS San Francisco, California, United States
  • Georgetown HIVTR-CCR5 Non-Network CRS Washington D.C., District of Columbia, United States
View Trial Details
Completed

An Open-Label Treatment Protocol to Provide Continued Elvucitabine Treatment

NCT00675844

Conditions
Blood-Borne Infections, Communicable Diseases, Genital Diseases, +11 more
Locations
  • Clinical Trial Site Orlando, Florida, United States
  • Clinical Trial Site Pensacola, Florida, United States
  • Clinical Trial Site Newark, New Jersey, United States
  • Clinical Trial Site Austin, Texas, United States
View Trial Details

Related conditions